SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed.

There are no approved treatments for nonrelapsing secondary progressive multiple sclerosis. In a phase 3, double-blind, placebo-controlled, event-driven trial, we randomly assigned participants ...

Stem cells from donated placentas appear safe and may help ease secondary progressive MS, a small open-label Phase 1 clinical ...

Around 150,000 people are living with the condition in the UK, while a further 7,100 are newly diagnosed each year ...

New research led by a St. Michael’s Hospital clinician-scientist and published in the prestigious New England Journal of ...

The following is a summary of “Secondary progression activity monitoring in MS despite an early highly active treatment the ...

The NHS has shared a tweet to raise awareness of multiple sclerosis (MS), an incurable condition that affects the central ...

HERCULES evaluated 1,131 non-relapsing secondary progressive MS patients with a median baseline EDSS of 6.0 who were randomized to tolebrutinib or placebo. In HERCULES, tolebrutinib slowed ...

A newly developed AI correctly judged with 90% accuracy when a person’s MS had transitioned to a stage where it will progress ...

The NHS has warned about potential symptoms of an incurable condition that profoundly affects the central nervous system.